Deal Watch: Bristol And Otsuka Pursue Oncolytic Virus Therapies Via Licensing Deals

 
• By Joseph Haas, Ian Haydock, and John Davis

Busy stretch before Christmas holidays sees two deals around oncolytic virus therapeutics, a Middle East partnership for Orexigen’s Contrave, immuno-oncology deals involving Pfizer and ElsaLys, and Roche and ImmuNext partnering to develop drugs targeting the VISTA pathway.

businessman and businesswoman are exchanging document or contract

More from Deals

More from Business